NaviGate Cardiac Structures, Inc.

NaviGate Cardiac Structures, Inc., (NCSI) is an early-stage company focused on developing transcatheter solutions for the treatment of atrioventricular valve regurgitation. The NaviGate valve-based technology was licensed from Cleveland Clinic and further modified and developed by NCSI.

The GATE™ Valve

The NCSI Team

The leadership team at NCSI includes a core group of professionals with considerable experience and expertise in the development of surgical and transcatheter replacement heart valves. You can learn more about NCSI’s leadership team below.

Peter W. J. Hinchliffe


Read More

Previously; Director of R&D, United States Surgical Corp. (now Medtronic), Founder and VP of R&D, Rex Medical (start-up), President and CEO Datascope Corp., Vascular Interventions, President and CEO Getinge Cardiac Systems, Jarvik Heart President and COO. Over 30 years of Medical Device Experience with over 100 issued US medical device patents and over 100 more pending.

R.C. Quijano

Chief Technology Officer

Read More

Founded Xenomedica AG, Switzerland; VP R&D, Regulatory and Clinical Affairs Edwards CVS; Founded VenPro Corp. venous valves replacement and first valve ever implanted in a human (now Melody, MDT) by catheter guided means; Founder 3f Therapeutics; Founder NaviGate Cardiac Structures, Inc. Over 30 years experience in replacement heart valves.

Pete Reynolds

Finance Director

Read More

Pete Reynolds – Finance Director with 25+ years experience in accounting and finance, Big 4 CPA, Ernst & Young, Senior Finance Executive roles in publicly traded and private equity owned portfolio companies (PacifiCare Health Systems, Skilled Healthcare, Apria).   Interim and fractional CFO roles in healthcare, distribution, medical device and luxury consumer products.